Ipamorelin Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous Frequency: 2–3 times daily (typically before meals and before bed) Dose Range: 100–300 mcg per injection, 2–3x daily Cycle Length: 8–12 weeks on, 4 weeks off; repeat as needed Timing: On empty stomach; at least 30 min before food. Best administered before bed (GH pulse amplification during sleep) and upon waking
Reconstitution
Vial Size: 5mg Water Volume: 2.5mL Concentration: 2mg/mL
Titration Schedule
Weeks 1–2: 100 mcg 2x daily Weeks 3–4: 200 mcg 2x daily Weeks 5+: 200–300 mcg 2–3x daily
Timeline & Pharmacokinetics
Onset: 15–30 minutes Peak Plasma: ~30–60 minutes Half-Life: ~2 hours Steady State: 2–4 weeks of daily dosing Time to Results: 2–4 weeks for sleep improvement; 8–12 weeks for body composition changes Washout: 1–2 weeks
Storage
Lyophilized: −20 °C (−4 °F) Reconstituted: 2–8 °C (35.6–46.4 °F) Shelf Life: 28 days
Injection Sites
Abdomen, Thigh, Upper arm
Safety & Contraindications
Safety: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
Contraindications: Active malignancy or personal/family history of cancer (GH promotes cell proliferation); Pregnancy and breastfeeding; Pituitary disorders or prior pituitary surgery
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
Ipamorelin vs GHRP-2: Which Offers More Targeted GH Release?
Ipamorelin and GHRP-2 both stimulate growth hormone release via the ghrelin receptor, but Ipamorelin provides more selective action with minimal impact on other hormones like ACTH and cortisol. GHRP-2 delivers stronger GH pulses alongside broader endocrine effects. Combining them can enhance overall GH output through additive receptor stimulation.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.